Project Grant R44DK105691

Federal Project Grant Award Summary The National Center for Advancing Translational Sciences (NCATS) awarded Columbia University in the City of New York a Project Grant totaling $451,136 (Award Date: May 1, 2026; Ultimate Completion Date: April 30, 2028) to advance RF-409, a first-in-class synthetic insulin receptor (IR) agonist designed to treat severe insulin resistance syndromes, including Donohue and Rabson-Mendenhall syndromes. The project delivers preclinical and translational research...

Federal Project Grant Award Summary Cornela Therapeutics Inc. received a $599,296 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective June 1, 2025, through November 30, 2026. The award supports enabling preclinical development studies for CMT-101, a novel adeno-associated virus (AAV)-based gene therapy targeting Glycogen Storage Disease Type 1B...

Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $442,071 Project Grant (R21 mechanism) from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), awarded on August 18, 2025, with a completion date of July 31, 2027. This award supports research into novel therapeutic approaches for congenital hyperinsulinism (CHI), a life-threatening infantile and childhood...

Federal Cooperative Agreement Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Cooperative Agreement totaling $194,654 to The Royal Institution For The Advancement Of Learning (McGill University) on September 10, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project, "Continuous Ketone Monitoring with the Use of SGLT2 Inhibitors in T1D," is led by Principal Investigator...

Federal Grant Award Summary Syntis Bio Inc. received a $694,032 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective September 17, 2025, with a completion date of August 31, 2026. The award supports the development of SYN-202, an oral methionine gamma-lyase (MGL) enzyme therapy designed to treat homocystinuria (HCU), a rare pediatric genetic disorder caused by...

Federal Project Grant Award Summary Children's Hospital Los Angeles received a $141,087 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded on September 30, 2025, with completion anticipated by April 30, 2027. The award funds investigative research examining the role of neurogenin 3 (NGN3) protein in repressing Notch signaling during pancreatic...

Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Indiana University Indianapolis a Project Grant totaling $811,217 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on February 18, 2026, with a completion date of January 31, 2031. This research grant supports a multi-principal investigator (MPI) investigation into the signaling mechanisms of ultra-stable and glucose-responsive...

Federal Grant Award Summary Boston Children's Hospital received a $168,543 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded May 1, 2026, with completion targeted for March 31, 2031. The grant supports biomedical research investigating the mechanisms of hypothalamic-pituitary-adrenal (HPA) axis suppression and recovery following long-term...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the Regents of the University of Michigan a $793,098 Project Grant on September 5, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate tirzepatide as a therapeutic treatment for familial partial lipodystrophy (FPLD). The research addresses a critical unmet medical need, as no FDA-approved therapy currently exists for FPLD in the United States. The...

Federal Project Grant Award Summary Syntis Bio Inc. received a $343,635 Project Grant award dated September 10, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop SYNT-213, a once-daily oral therapeutic treatment for Maple Syrup Urine Disease (MSUD). The project, which concludes August 31, 2026, aims to optimize a novel solid dosage formulation that...